Targeted Therapy

MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.

Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.

Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.

Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

CCA News Print Edition

CCA News Weekly e‑Newsletter

I have reviewed and consent to the terms of CCA News's Privacy Policy, and CCA News has my permission to retain my information in its database, and to forward pertinent communications to me.